Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01229865 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
A Phase 2 study of Differential Thyroid Cancer, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT01229865 is a Phase 2 study of Differential Thyroid Cancer that has completed, run by Vascular Biogenics Ltd. operating as VBL Therapeutics. The registered enrollment target is 29 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT01229865, a Phase 2 study of Differential Thyroid Cancer, has completed, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.
Conditions Studied
Interventions
- DRUG VB-111
Study Locations (3)
Florida
- Mayo Clinic - Jacksonville
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01229865
The ClinicalTrials.gov registry entry for NCT01229865 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Differential Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which VB-111 is the first listed.
NCT01229865 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Massachusetts, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01229865 about?
NCT01229865 is a clinical study titled "Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer". The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.
What is the current status of trial NCT01229865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2010-12. Estimated completion is 2016-06.
What conditions does trial NCT01229865 study?
This clinical trial studies the following conditions: Differential Thyroid Cancer.
What interventions are being tested in trial NCT01229865?
The interventions under investigation include: VB-111 (DRUG).
Who is sponsoring clinical trial NCT01229865?
This trial is sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01229865 being conducted?
This trial has 3 study locations across Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.